Literature DB >> 35396132

Validation of automated body composition analysis using diagnostic computed tomography imaging in patients with pancreatic cancer.

Ali N Gunesch1, Thomas L Sutton2, Stephanie M Krasnow3, Christopher R Deig4, Brett C Sheppard2, Daniel L Marks5, Aaron J Grossberg6.   

Abstract

BACKGROUND: Sarcopenia is associated with complications and inferior oncologic outcomes in solid tumors. Axial computed tomography (CT) scans can be used to evaluate sarcopenia, however manual quantification is laborious. We sought to validate an automated method of quantifying muscle cross-sectional area (CSA) in patients with pancreatic adenocarcinoma (PDAC).
METHODS: Mid-L3 CT images from patients with PDAC were analyzed: CSAs of skeletal muscle (SM) were measured using manual segmentation and the software AutoMATiCA, and then compared with linear regression.
RESULTS: Five-hundred-twenty-five unique scans were analyzed. There was robust correlation between manual and automated segmentation for L3 CSA (R2 0.94, P < 0.001). Bland-Altman analysis demonstrated a consistent overestimation of muscle CSA by AutoMATiCA with a mean difference of 5.7%. A correction factor of 1.06 was validated using a unique test dataset of 36 patients with non-PDAC peripancreatic malignancies.
CONCLUSIONS: Automated muscle CSA measurement with AutoMATiCA is highly efficient and yields results highly correlated with manual measurement. These findings support the potential use of high-throughput sarcopenia analysis with abdominal CT scans for both clinical and research purposes.
Copyright © 2022 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AutoMATiCA; Body composition; Muscle mass; Pancreatic ductal adenocarcinoma; Sarcopenia

Mesh:

Year:  2022        PMID: 35396132      PMCID: PMC9308682          DOI: 10.1016/j.amjsurg.2022.03.025

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   3.125


  19 in total

1.  Automated body composition analysis of clinically acquired computed tomography scans using neural networks.

Authors:  Michael T Paris; Puneeta Tandon; Daren K Heyland; Helena Furberg; Tahira Premji; Gavin Low; Marina Mourtzakis
Journal:  Clin Nutr       Date:  2020-01-22       Impact factor: 7.324

2.  Prognostic impact of early nutritional support in patients affected by locally advanced and metastatic pancreatic ductal adenocarcinoma undergoing chemotherapy.

Authors:  Ilaria Trestini; Luisa Carbognin; Isabella Sperduti; Clelia Bonaiuto; Alessandra Auriemma; Davide Melisi; Lisa Salvatore; Emilio Bria; Giampaolo Tortora
Journal:  Eur J Clin Nutr       Date:  2018-03-26       Impact factor: 4.016

3.  Impact Total Psoas Volume on Short- and Long-Term Outcomes in Patients Undergoing Curative Resection for Pancreatic Adenocarcinoma: a New Tool to Assess Sarcopenia.

Authors:  Neda Amini; Gaya Spolverato; Rohan Gupta; Georgios A Margonis; Yuhree Kim; Doris Wagner; Neda Rezaee; Matthew J Weiss; Christopher L Wolfgang; Martin M Makary; Ihab R Kamel; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2015-04-30       Impact factor: 3.452

Review 4.  Influence of cachexia and sarcopenia on survival in pancreatic ductal adenocarcinoma: a systematic review.

Authors:  I Ozola Zalite; R Zykus; M Francisco Gonzalez; F Saygili; A Pukitis; S Gaujoux; R M Charnley; V Lyadov
Journal:  Pancreatology       Date:  2014-12-04       Impact factor: 3.996

5.  Sarcopenia is an independent predictor of complications following pancreatectomy for adenocarcinoma.

Authors:  Savita Joglekar; Aeen Asghar; Sarah L Mott; Benjamin E Johnson; Anna M Button; Eve Clark; James J Mezhir
Journal:  J Surg Oncol       Date:  2014-12-29       Impact factor: 3.454

Review 6.  Body composition assessment and sarcopenia in patients with pancreatic cancer: a systematic review and meta-analysis.

Authors:  James Bundred; Sivesh K Kamarajah; Keith J Roberts
Journal:  HPB (Oxford)       Date:  2019-06-29       Impact factor: 3.647

7.  Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer.

Authors:  Benjamin H L Tan; Laura A Birdsell; Lisa Martin; Vickie E Baracos; Kenneth C H Fearon
Journal:  Clin Cancer Res       Date:  2009-11-03       Impact factor: 12.531

8.  The impact of sarcopenia and myosteatosis on outcomes of unresectable pancreatic cancer or distal cholangiocarcinoma.

Authors:  Katie E Rollins; Nilanjana Tewari; Abigail Ackner; Amir Awwad; Srinivasan Madhusudan; Ian A Macdonald; Kenneth C H Fearon; Dileep N Lobo
Journal:  Clin Nutr       Date:  2015-09-01       Impact factor: 7.324

9.  A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care.

Authors:  Marina Mourtzakis; Carla M M Prado; Jessica R Lieffers; Tony Reiman; Linda J McCargar; Vickie E Baracos
Journal:  Appl Physiol Nutr Metab       Date:  2008-10       Impact factor: 2.665

10.  Exercise Medicine in the Management of Pancreatic Cancer: A Systematic Review.

Authors:  Hao Luo; Daniel A Galvão; Robert U Newton; Pedro Lopez; Colin Tang; Ciaran M Fairman; Nigel Spry; Dennis R Taaffe
Journal:  Pancreas       Date:  2021-03-01       Impact factor: 3.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.